

Patient number	Tumor type	Gender	Age range (years)	Stage	TNM classification	Pathological subtype	Molecular status
LC_1	LC	Female	70-75	IIA	pT2bNOM0	Squamous cell carcinoma	
LC_2	LC	Male	86-90	IB	pT2bNOM0	Squamous cell carcinoma	
LC_3	LC	Male	66-70	IIIB	pT4N2M0	Adenocarcinoma	
LC_4	LC	Female	60-65	IIB	pT2aN1M0	Adenocarcinoma	
LC_5	LC	Male	60-65	IA3	pT1cNOM0	Large cell carcinoma	
LC_6	LC	Male	60-65	IIIA	pT4N1M0	Adenocarcinoma	
LC_7	LC	Male	60-65	IB	pT2aNOM0	Squamous cell carcinoma	
LC_8	LC	Female	50-55	IIB	pT3NOM0	Pleiomorphic carcinoma	
OvC_1	OvC	Female	70-75	IIIC	pT3cNxM0	High grade serous carcinoma	
OvC_2	OvC	Female	50-55	IVB	pT3cNxM1b	High grade serous carcinoma	
OvC_3	OvC	Female	60-65	IVB	pT3cNxM1b	High grade serous carcinoma	BRCA+
OvC_4	OvC	Female	80-85	IVB	pT3cNxM1b	High grade serous + clear cell carcinoma (mix)	
OvC_5	OvC	Female	60-65	IA	pT1cNOM0	High grade serous carcinoma	
CRC_1	CRC	Female	80-85	IIB	pT4aNOM0	Right caecum, global moderately differentiated adenocarcinoma with mixed glandular, mucinous growth pattern, moderate budding	MSI-high
CRC_2	CRC	Female	86-90	IIIB	pT3N1bM0	Left rectosigmoid, moderately differentiated adenocarcinoma NST	MSS
CRC_3	CRC	Female	50-55	IVA	pT4aN1aM1a	Left sigmoid, moderately differentiated adenocarcinoma	MSS
CRC_4	CRC	Male	80-85	I	pT2NOM0	Left sigmoid, moderately differentiated adenocarcinoma	MSS
CRC_5	CRC	Male	50-55	IIA	pT3NOL1	Left sigmoid, moderately differentiated adenocarcinoma	MSS
CRC_6	CRC	Female	76-80	IIIB	pT3N1aM0	Right caecum, moderately differentiated adenocarcinoma NOS	MSS
CRC_7	CRC	Male	80-85	IIA	pT3NOL1	Right ascending, moderately differentiated adenocarcinoma	MSS
BC_1	BC	Female	40-45	III	pT1cNOM0	Invasive ductal carcinoma	HER2 positive
BC_2	BC	Female	50-55	III	pT2NOM0	Invasive ductal carcinoma	Triple negative
BC_3	BC	Female	50-55	III	pT3NOM0	Invasive ductal carcinoma	Triple negative
BC_4	BC	Female	86-90	III	pT1NOM0	Invasive ductal carcinoma	Triple negative
BC_5	BC	Female	60-65	III	pT2N1aM0	Invasive apocrine carcinoma	Triple negative
BC_6	BC	Female	70-75	III	pT2NOM0	Invasive ductal carcinoma	HER2 positive
BC_7	BC	Female	80-85	III	pT3NOM0	Metaplastic carcinoma	Triple negative
BC_8	BC	Female	60-65	III	pT3NOM0	Invasive ductal carcinoma	HER2 positive
BC_9	BC	Female	40-45	III	pT2N1M0	Invasive ductal carcinoma	Luminal-HER2+
BC_10	BC	Female	50-55	III	pT2NOM0	Invasive ductal carcinoma	Triple negative
BC_11	BC	Female	46-50	III	pT1cNOM0	Invasive ductal carcinoma	Triple negative
BC_12	BC	Female	76-80	III	pT2NxM0	Invasive ductal carcinoma	Triple negative
BC_13	BC	Female	60-65	III	pT2N1M0	Invasive ductal carcinoma	Luminal B-like
BC_14	BC	Female	46-50	II	pT2N1M0	Invasive ductal carcinoma	Luminal A-like
BC_15	BC	Female	66-70	III	pT1NOM0	Invasive ductal carcinoma	Triple negative
BC_16	BC	Female	60-65	III	pT2N1M0	Invasive ductal carcinoma	Luminal B –like

Supplementary Table S1: Characteristics of the patients included in this study. Included cancer types are lung cancer (LC), ovarian cancer (OvC), colorectal cancer (CRC) and breast cancer (BC). Microsatellite Instable (MSI), microsatellite stable (MSS), Human epidermal growth factor receptor 2 (HER2). Please see Table S3 for tumour mutation signatures.